Spotlight -

PBMI Innovators|

2026 State of Pharmacy survey results available now|

Our July 2026 issue

Opinion|Videos|October 14, 2025

Balancing Treatment Burden, Access Barriers, and Future Research of BCG-Unresponsive NMIBC

Author(s)Max Kates, MD

An expert discusses how treatment decisions must balance short-term burden with long-term benefits while avoiding protocol-driven step therapy requirements, as future comparative effectiveness trials and real-world evidence will better inform individualized patient care strategies.

Episodes in this series

1 expert in this video

EP. 1 Evolving Guidelines: Impact of Gene Therapy and BCG Failure Redefinitions on High-Risk NMIBC Patient Management

1 expert in this video

EP. 2 Applying Evidence Standards to Guide Gene Therapy Use in BCG-Unresponsive NMIBC

1 expert in this video

EP. 3 Impact of Real-World Treatment Experience on Gene Therapy Uptake in NMIBC

1 expert in this video

EP. 4 Navigating Challenges and Impact on Workflow with New NMIBC Therapies in Practice

1 expert in this video

EP. 5 Effective Strategies for Clinics Preparing to Implement Gene Therapy Into NMIBC Treatment Workflows

1 expert in this video

EP. 6 Reducing Clinical Resource Burden: Impact of Less Frequent NMIBC Therapy Administration

1 expert in this video

EP. 7 How Community-Based Gene Therapy Is Changing Treatment and Improving Quality of Life for Patients With BCG-Unresponsive NMIBC

1 expert in this video

EP. 8 Understanding NMIBC and Its Risk Factors

1 expert in this video

EP. 9 Navigating Treatment Burden in NMIBC

1 expert in this video

EP. 10 When BCG Falls Short: What’s Next for NMIBC Patients?

1 expert in this video

EP. 11 A New Era: The Rise of Gene Therapy in NMIBC

1 expert in this video

EP. 12 Where Do We Go From Here? Overcoming Barriers in NMIBC Care

EP. 13 Bridging the Gap Between Clinical Trial Evidence and Real-World Practice in NMIBC

1 expert in this video

EP. 14 Coverage Criteria and Clinical Evidence Used to Shape Health Plan Formulary Decisions in BCG-Unresponsive NMIBC

1 expert in this video

EP. 15 Prioritizing Safety and Efficacy: Role of Guidelines in NMIBC Formulary Decisions

1 expert in this video

EP. 16 Evaluating Cost-Effectiveness of NMIBC Therapies From a Health Plan Perspective

1 expert in this video

EP. 17 Leveraging Real-World Evidence in NMIBC Therapy Evaluations

1 expert in this video

EP. 18 Administration Matters: How Dosing Frequency and Toxicity Shape NMIBC Coverage Decisions

1 expert in this video

EP. 19 Access Barriers in NMIBC: Financial, Operational and Systemic Challenges With Emerging Therapies

1 expert is featured in this series.

EP. 20 Understanding the Clinical Needs and Real-World Data in BCG-Unresponsive NMIBC

1 expert is featured in this series.

EP. 21 Evaluating Emerging NMIBC Therapies Through Long-Term Data and Real-World Outcomes

1 expert is featured in this series.

EP. 22 Balancing Treatment Burden, Access Barriers, and Future Research of BCG-Unresponsive NMIBC

Newsletter

Get the latest industry news, event updates and more from Managed Healthcare Executive.

Related Content

The rationale for active surveillance and determining when radiation is appropriate

ByChristina Poh, M.D.

August 26th 2026

An overview of the epidemiology and treatment of follicular lymphoma

ByChristina Poh, M.D.

August 26th 2026

2 experts are featured in this series

BE BOLD Efficacy and Safety Data: Comparing Bimekizumab and Risankizumab on Joint-Centric Endpoints

ByPhilip Mease, MD, MACR,Saakshi Khattri, MD

August 24th 2026

2 experts are featured in this series

Communicating with Payers: Practical Guidance for Sparsentan Access in FSGS

ByKirk Campbell, MD,Howard Trachtman, MD

August 20th 2026

2 experts are featured in this series

FSGS Payer Policy: Aligning Coverage with the Sparsentan Label

ByKirk Campbell, MD,Howard Trachtman, MD

August 20th 2026

Latest CME

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; Anne S. Tsao, MD, MBA

27th Annual International Lung Cancer Congress®

27th Annual International Lung Cancer Congress®

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

Tennessee Oncology Practice Society

Tennessee Oncology Practice Society

2 Sessions are Available!

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Millie Das, MD; Wade Iams, MD, MSCI; Ruham Nasany, MD

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

Show Me the Data™: Incorporating the Latest Advances in Immunotherapy and EGFR-Targeted Treatments for Resectable, Early-Stage NSCLC

Show Me the Data™: Incorporating the Latest Advances in Immunotherapy and EGFR-Targeted Treatments for Resectable, Early-Stage NSCLC

Mara Antonoff, MD, FACS; Laura Alder, MD; Stephanie Worrell, MD, FACS

Trending on Managed Healthcare Executive

Zepbound linked to lower healthcare costs in older adults with obesity

FDA approves Gilead’s Bixlenvo, smallest single-tablet option for virologically suppressed HIV patients

Biosimilars provide modest cost savings for cancer patients, study finds

FDA approves brepocitinib for rare skin disease

Employer health care costs projected to rise 9.5% in 2027, report finds